Caisse De Depot Et Placement Du Quebec decreased its stake in Citigroup Inc (C) by 6.63% based on its latest 2018Q1 regulatory filing with the SEC. Caisse De Depot Et Placement Du Quebec sold 144,600 shares as the company’s stock declined 11.86% with the market. The institutional investor held 2.04M shares of the major banks company at the end of 2018Q1, valued at $137.49M, down from 2.18M at the end of the previous reported quarter. Caisse De Depot Et Placement Du Quebec who had been investing in Citigroup Inc for a number of months, seems to be less bullish one the $172.45B market cap company. The stock increased 0.37% or $0.25 during the last trading session, reaching $67.63. About 16.55M shares traded. Citigroup Inc. (NYSE:C) has risen 10.48% since June 22, 2017 and is uptrending. It has underperformed by 2.09% the S&P500. Some Historical C News: 20/03/2018 – GEM DIAMONDS LTD GEMD.L : CITIGROUP RAISES TO BUY; 31/05/2018 – MOODY’S: THE DEPLOYMENT OF PEOPLE, CAPITAL AND TECHNOLOGY BY GLOBAL INVESTMENT BANKS WILL DEFINE WHICH INSTITUTIONS ADVANCE AMID INTENSE COMPETITION; 07/05/2018 – Activist Investor ValueAct Has a Roughly $1.2 Billion Stake in Citigroup — Letter; 10/05/2018 – SHANKARA BUILDING PRODUCTS – APPROVED RENEWAL OF WORKING CAPITAL LIMITS FROM CITI BANK, KOTAK MAHINDRA BANK, INDUSIND BANK AND AXIS BANK; 08/05/2018 – AMERICAN AXLE & MANUFACTURING HOLDINGS INC AXL.N : CITIGROUP RAISES TARGET PRICE TO $23 FROM $20; 24/04/2018 – Citi chairman says all options on table to find his replacement; 07/05/2018 – ValueAct reveals $1.2bn stake in Citigroup; 08/05/2018 – CONTINENTAL RESOURCES INC CLR.N : CITIGROUP RAISES TARGET PRICE TO $65 FROM $62; 29/03/2018 – BP PLC BP.L : CITIGROUP RAISES TARGET PRICE TO 545P FROM 510P; 13/04/2018 – CITIGROUP CFO: CORPORATE ACTIVITY WAS ROBUST AROUND THE WORLD
Clearbridge Investments Llc increased its stake in Mylan N V (MYL) by 3.97% based on its latest 2018Q1 regulatory filing with the SEC. Clearbridge Investments Llc bought 97,098 shares as the company’s stock declined 5.74% with the market. The institutional investor held 2.54 million shares of the major pharmaceuticals company at the end of 2018Q1, valued at $104.63 million, up from 2.44 million at the end of the previous reported quarter. Clearbridge Investments Llc who had been investing in Mylan N V for a number of months, seems to be bullish on the $19.91B market cap company. The stock decreased 0.62% or $0.24 during the last trading session, reaching $38.63. About 1.76M shares traded. Mylan N.V. (NASDAQ:MYL) has declined 1.13% since June 22, 2017 and is downtrending. It has underperformed by 13.70% the S&P500. Some Historical MYL News: 20/03/2018 – MYLAN LAUNCHES GENERIC OF BRISTOL MYERS’ MUTAMYCIN INJECTION; 20/03/2018 – Mylan Adds to Oncology Portfolio With Launch of Generic Mutamycin Injection; 09/05/2018 – MYLAN 1Q REV. $2.68B, EST. $2.74B; 28/03/2018 – Mylan Introduces Symfi™ Triple Combo Once-Daily HIV Treatment in the U.S; 17/05/2018 – FDA names drugmakers likely blocking access to branded drug samples; 14/05/2018 – Ascend Capital Adds Time Warner, Exits AT&T, Cuts Mylan: 13F; 09/05/2018 – Mylan Backs 2018 View of Adj EPS $5.20-Adj EPS $5.60; 06/04/2018 – CAFC: SHIRE DEVELOPMENT, LLC v. MYLAN PHARMACEUTICALS INC. [RULE 36 JUDGMENT] – Appeal #17-2268 – 2018-04-06; 12/03/2018 – Hikma Pharmaceutical: FDA Requests Additional Clinical Study for Generic Advair; 11/04/2018 – MYLAN NV -CO, FUJIFILM KYOWA KIRIN BIOLOGICS CONTINUE TO NEGOTIATE FOR COMMERCIALIZING PRODUCT IN ADDITIONAL TERRITORIES
Analysts await Citigroup Inc. (NYSE:C) to report earnings on July, 13. They expect $1.56 EPS, up 22.83% or $0.29 from last year’s $1.27 per share. C’s profit will be $3.98 billion for 10.84 P/E if the $1.56 EPS becomes a reality. After $1.68 actual EPS reported by Citigroup Inc. for the previous quarter, Wall Street now forecasts -7.14% negative EPS growth.
Among 41 analysts covering Citigroup Inc. (NYSE:C), 25 have Buy rating, 2 Sell and 14 Hold. Therefore 61% are positive. Citigroup Inc. had 127 analyst reports since July 21, 2015 according to SRatingsIntel. The firm has “Neutral” rating by Credit Suisse given on Monday, December 21. As per Wednesday, August 26, the company rating was downgraded by JP Morgan. The firm earned “Buy” rating on Friday, August 18 by RBC Capital Markets. The stock has “Sell” rating by Societe Generale on Monday, October 16. The rating was maintained by Oppenheimer on Monday, March 26 with “Buy”. The company was maintained on Monday, July 17 by Nomura. The stock has “Market Perform” rating by Wood on Monday, April 18. The firm has “Equal-Weight” rating given on Monday, October 26 by Morgan Stanley. The stock has “Hold” rating by Keefe Bruyette & Woods on Wednesday, April 4. The stock of Citigroup Inc. (NYSE:C) earned “Neutral” rating by Susquehanna on Tuesday, October 6.
More notable recent Citigroup Inc. (NYSE:C) news were published by: Bizjournals.com which released: “What’s North Carolina’s piece of the $100M Citigroup settlement?” on June 15, 2018, also Streetinsider.com with their article: “Citigroup (C) Releases Certain Disclosures Required by Federal Reserve Stress Tests” published on June 21, 2018, 247Wallst.com published: “Why GE’s Dow Jones Industrial Average Removal May Be Biggest Buy Sign Ever” on June 21, 2018. More interesting news about Citigroup Inc. (NYSE:C) were released by: Investorplace.com and their article: “3 Key Bank Stocks Ahead of the Stress Tests” published on June 20, 2018 as well as Seekingalpha.com‘s news article titled: “Citigroup Will Thrive Regardless Of Interest Rates” with publication date: June 08, 2018.
Caisse De Depot Et Placement Du Quebec, which manages about $41.31 billion US Long portfolio, upped its stake in Northern Trust Corp (NASDAQ:NTRS) by 124,500 shares to 150,008 shares, valued at $15.47 million in 2018Q1, according to the filing. It also increased its holding in Sprint Corp (NYSE:S) by 626,900 shares in the quarter, for a total of 2.80 million shares, and has risen its stake in Ggp Inc.
Since February 27, 2018, it had 0 buys, and 7 selling transactions for $5.91 million activity. Another trade for 6,466 shares valued at $500,666 was sold by Forese James A.. The insider Callahan Don sold 7,000 shares worth $536,410. Shares for $263,126 were sold by MURRAY JOSEPH MICHAEL on Tuesday, February 27. 32,400 shares were sold by Fraser Jane Nind, worth $2.51M. 8,010 Citigroup Inc. (NYSE:C) shares with value of $611,804 were sold by Hu W. Bradford.
Investors sentiment decreased to 0.89 in Q1 2018. Its down 0.18, from 1.07 in 2017Q4. It turned negative, as 89 investors sold C shares while 499 reduced holdings. 114 funds opened positions while 412 raised stakes. 1.90 billion shares or 4.45% less from 1.99 billion shares in 2017Q4 were reported. 49,976 are held by National Bank Hapoalim Bm. Sg Americas Secs Llc has invested 0.53% in Citigroup Inc. (NYSE:C). L & S Advsr reported 89,973 shares or 1.16% of all its holdings. Qs Invsts Ltd Liability Corporation has 0.14% invested in Citigroup Inc. (NYSE:C). Eagle Cap Mgmt Lc stated it has 2.11% of its portfolio in Citigroup Inc. (NYSE:C). Veritable LP owns 0.11% invested in Citigroup Inc. (NYSE:C) for 79,020 shares. Etrade Capital Mgmt Limited Liability Corp owns 38,768 shares or 0.08% of their US portfolio. Family Mngmt Corporation holds 2.73% of its portfolio in Citigroup Inc. (NYSE:C) for 53,747 shares. California-based Wells Fargo & Mn has invested 0.27% in Citigroup Inc. (NYSE:C). Systematic Fincl Management LP stated it has 0.19% in Citigroup Inc. (NYSE:C). Swedbank holds 0.77% in Citigroup Inc. (NYSE:C) or 2.20 million shares. 6,793 were reported by Burns J W And. Lockheed Martin Invest has 62,000 shares. Foundation Asset Management Ltd Partnership has 60,000 shares. Moreover, Cibc Markets Corporation has 0.24% invested in Citigroup Inc. (NYSE:C).
More recent Mylan N.V. (NASDAQ:MYL) news were published by: Seekingalpha.com which released: “Mylan: A Margin Of Safety Case Study” on June 04, 2018. Also Seekingalpha.com published the news titled: “Amgen Should Rebound On Aimovig And Kyprolis Revenue” on June 20, 2018. Streetinsider.com‘s news article titled: “Mylan (MYL) Announces Launch of Generic Angiomax Injection” with publication date: June 18, 2018 was also an interesting one.
Among 23 analysts covering Mylan Inc. (NASDAQ:MYL), 16 have Buy rating, 0 Sell and 7 Hold. Therefore 70% are positive. Mylan Inc. has $85 highest and $3000 lowest target. $51.22’s average target is 32.59% above currents $38.63 stock price. Mylan Inc. had 77 analyst reports since July 27, 2015 according to SRatingsIntel. Morgan Stanley maintained Mylan N.V. (NASDAQ:MYL) rating on Monday, August 7. Morgan Stanley has “Equal-Weight” rating and $36 target. Leerink Swann maintained Mylan N.V. (NASDAQ:MYL) on Monday, August 15 with “Outperform” rating. RBC Capital Markets maintained it with “Hold” rating and $3300 target in Friday, August 4 report. The firm has “Equal Weight” rating by Barclays Capital given on Monday, September 21. The firm earned “Buy” rating on Wednesday, October 26 by Mizuho. UBS maintained it with “Buy” rating and $60 target in Monday, October 10 report. The rating was maintained by Wells Fargo with “Hold” on Thursday, January 18. The stock of Mylan N.V. (NASDAQ:MYL) earned “Overweight” rating by JP Morgan on Wednesday, November 18. As per Tuesday, May 29, the company rating was maintained by Bank of America. The rating was maintained by Deutsche Bank on Friday, August 7 with “Buy”.